Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

The 72-week multinational phase 3 ATTAIN-2 trial randomized 1613 participants with obesity or overweight (BMI ≥ 27.0) and T2D ...

Worldwide names John Capicchioni as SVP, Commercial, Early Phase to lead business development and commercial activities for ...

"Eledon takes transplant rejection therapy to Phase III on mixed results" was originally created and published by Clinical ...

Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical ...

Clinical trials are studies that test new medical interventions, such as a new type of drug, surgery, or medical device, on human volunteers. They aim to determine whether the new treatment option is ...

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- ...

Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a condition for ...

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health (CVD) report ...

Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...